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Abstract 
 Despite the development of several injectable or oral treatments for relapsing-
remitting multiple sclerosis (RRMS), it remains difficult to treat patients with 
aggressive disease, and many of these continue to develop severe disability. During 
the last two decades autologous hematopoietic stem cell transplantation (aHSCT) 
has been explored with the goal to eliminate an aberrant immune system and then 
re-install a healthy and tolerant one from hematopoietic precursor cells that had been 
harvested from the patient prior to chemotherapy. Clinical studies have shown that 
aHSCT is able to completely halt disease activity in the majority of patients with 
aggressive RRMS. Research on the mechanisms of action supports that aHSCT 
indeed leads to renewal of a healthy immune system. Below we will summarize 
important aspects of aHSCT and mention the currently best-examined regimen.   
 
Introduction 
 Multiple sclerosis (MS) is considered a prototypical T cell-mediated 
autoimmune disease that develops based on a complex genetic background and 
additional environmental triggers such as infection with Epstein Barr virus (EBV), low 
vitamin D3 levels and smoking [1, 2]. Pathogenetically, MS is characterized by 
inflammatory lesions in the central nervous system (CNS), which lead to 
demyelination, incomplete remyelination, and also to neuronal/axonal damage and 
glial proliferation. Clinically, MS causes bouts of neurological deficits, in most 
instances problems of vision, sensory- and motor deficits, but also ataxia, and 
compromise of neurocognitive and autonomous functions. Relapses usually resolve 
after days and weeks during earlier stages of the disease, but remit only incompletely 
or not at all later. MS is heterogeneous in almost every respect including clinical 
presentation, disease course, imaging findings, the extent and destructiveness of 
inflammation and also of neurodegenerative aspects such as demyelination and loss 
of axons or CNS tissue in general, and finally the response to treatment.  
 The development of treatments for MS has been very successful, eight drugs 
are currently available and multiple others either already filed for approval or in late 
stage clinical development. However, due to the chronic nature of MS, all of these 
need to be given for long times or forever. Further, all of these have side effects and 
some of them very serious ones, and, depending on their route of administration, 
some treatments compromise the quality of life. Also, most of these are very 
expensive, and lead to substantial socioeconomic burden. All currently available 
disease-modifying treatments of MS are only effective during the earlier stages of 
disease, when autoimmune inflammation drives the disease process and before too 
much CNS tissue is irreversibly damaged. The current goals of treatment are 
therefore to institute MS treatment as early as possible and ideally to halt the disease 
process completely or at least for as long as possible. In a relatively small percentage 
of patients MS is so active and relapses or CNS lesions occur so frequently that one 
has to escalate treatment intensity and start treatments that are more effective, but 
also have more side effects. Despite these measures relapses can sometimes not be 
halted, and it is in these patients where we clearly need additional options.  
 Autologous hematopoietic stem cell transplantation (aHSCT) has evolved as 
one if not the best option to treat aggressive forms of MS, although acceptance 
among neurologists is still low. The reasons for this include the fact that mostly 
secondary- or primary progressive MS patients have been treated in earlier studies, 
and these responded only incompletely and/or were more prone to develop 
complications [3]. Further, the prevailing perception is that risk is still very high, i.e. 
mortality ranges up to 10%, which is not correct. In recent years, aHSCT has 
advanced substantially, and transplant-related mortality has been between 1-1.5% 
since 2000 with the BEAM-ATG regimen [4]. Through tight collaboration between 
hematologists/transplant specialists and neurologists aHSCT is now more 
standardized, mortality is within the range of the most active approved therapy, i.e. 
mitoxantrone, the efficacy is likely superior to all other available treatments, its 
mechanisms are better understood, and aHSCT is probably the only treatment of MS 
that has to be applied only once with no further need for therapy in the majority of 
patients, provided that they have been selected carefully. Despite all this, formal 
proof through a phase III clinical trial is still lacking mainly because testing such a 
treatment regimen is not supported by pharmaceutical industry, but pursued by 
academic investigators. Below, we will summarize the most important aspects of 
aHSCT and give a recommendation, how it should be applied in patients with 
aggressive disease, which is based on consensus meetings and continuous 
discussions between investigators in Europe and North America. 
 
 
  
MS treatment landscape  
 Current treatments of multiple sclerosis aim at reducing relapses and 
preventing or slowing progression of neurological disability in the most common form 
of MS, which at the time of first disease manifestation such as for example optic 
neuritis or myelitis is called clinically isolated syndrome (CIS). Once a second relapse 
occurs that affects a different functional system of the central nervous system (CNS) 
or when imaging findings indicate dissemination in time and space, the diagnosis of 
relapsing-remitting MS (RRMS) is made, which evolves into secondary progressive 
MS (SPMS) with or without relapses after various time intervals. CIS-RRMS-SPMS 
affects 80-85% of patients, and only approximately 10% of cases show disease 
progression from the beginning (primary progressive MS; PPMS). With respect to 
disease severity MS runs a benign course and never leads to substantial disability in 
a minority of patients, and, also relatively rarely MS can be aggressive and lead to 
death in a few years. MS relapses are treated with high dose intravenous or oral 
corticosteroids or, in the case of incomplete responses and severe relapses, by 
plasmapheresis. Available disease modifying drugs are either immunomodulatory or 
immunosuppressive and hence are effective during the inflammatory, relapsing-
remitting phase of the disease.  
 Different from other neurological diseases such as stroke or Alzheimer´s 
disease drug development for MS has been very successful, and we have now 
several first-line treatments for RRMS. Interferon-β (IFN-β) and glatiramer-acetate 
(GA) are already approved for up to two decades and have moderate efficacy and a 
favorable, well-known and benign side effect profile. Depending on the country, a 
recently introduced oral compound, fingolimod, is available as first-line or second-line 
and orally administered drug. Fingolimod, a sphingosin-1 phosphate receptor 
agonist, is considerably more effective than IFN- and GA and overall also well 
tolerated. Other oral medications are either already approved and will be available 
shortly (teriflunomide) or have been filed for approval after successful phase III 
testing (dimethyl-fumarate; laquinimod). The most effective currently available 
treatment is natalizumab, a humanized monoclonal antibody against CD49d/very late 
antigen-4 (VLA-4), which is generally also well tolerated, but has led to progressive 
multifocal leukoencephalopathy (PML), an opportunistic and often fatal infection of 
the brain by the polyoma virus JC, in over 300 patients so far. A chemotherapeutic 
agent, mitoxantrone, is used as second-line therapy for more severe RRMS and also 
for SPMS [5]. Mitoxantrone can only be given for a very limited period of time due to 
its cardiac toxicity, and secondary leukemias have occurred in up to 2.8% of MS 
patients treated with mitoxantrone. Regarding injectable or infusible compounds, 
several monoclonal antibodies have finished or are about to finish phase III clinical 
testing (anti-CD25, daclizumab; anti-CD20, ocrelizumab) or have already been filed 
for approval (anti-CD52, alemtuzumab). Furthermore, various other drugs and 
treatment approaches including oral- and injectable compounds, tolerization 
strategies with peptides, peptide-coupled cells or inactivated autoreactive T cells, 
immunomodulation with mesenchymal stem cells and immune reconstitution with 
autologous hematopoietic stem cells (aHSCT) are currently being tested at different 
stages of clinical development.   
 Based on longer time follow-up data from testing IFN-β in CIS, which 
demonstrated that the conversion to RRMS can be prolonged and that disability 
evolution can also be slowed by early treatment [6, 7], the prevailing tendency today 
is to treat patients early. Another strong argument for early treatment is that CNS 
tissue, despite its ability of functional compensation of certain deficits, has only a very 
limited capacity for repair at the structural level. As a consequence, MS treatments 
are most effective during the inflammatory RRMS phase of the disease and have little 
or no influence once a certain disability level and CNS damage have occurred and 
when SPMS has begun. It is generally accepted that immunomodulatory or even 
immunosuppressive treatments are not effective in SPMS, and that it is imperative 
therefore to initiate treatment as early as possible in order to prevent disability 
accrual as much as possible. However, depending on the drug label and approval of 
the various therapies in different countries, it may not be possible to start treatment 
with the most effective drug/s. Furthermore, since MS primarily affects young adults 
and is a chronic, life-long disease, the route of administration and adverse event 
profile of the respective treatment, the patient´s wish to have children and other 
aspects have to be taken into consideration. Some of the above drugs, e.g. 
mitoxantrone or alemtuzumab, have long-lasting effects on the hematopoietic system 
or carry the risk of secondary malignancies and cardiac damage (mitoxantrone) or of 
secondary autoimmune diseases (alemtuzumab). Natalizumab may lead to PML with 
increasing risk following 2 years of treatment or even higher risk following prior 
treatment with chemotherapeutic agents such as mitoxantrone. Hence, treatment 
decisions, i.e. how to begin and escalate therapy and which drug can be given or not 
after which prior medications, are not easy and need to take into account the severity 
and prognosis of MS in the individual patient, the prior treatment history, and the 
long-term adverse profile of the drugs and treatments.  
 
Autologous hematopoietic stem cell transplantation – current status 
 As reviewed by Saccardi and Mancardi [4], numerous aspects of aHSCT 
including different stem cell mobilization and conditioning regimens, which patients 
are best suited, the percentage of progression-free survival, and which factors 
contribute to risk have been examined in detail. More than 500 MS patients have 
received aHSCT in Europe alone in the last 20 years, and follow-up for substantial 
fraction of these is longer than 10 years. A joint study of the European and American 
Bone Marrow Transplantation Societies on long-term outcomes after HSCT in MS is 
currently ongoing. Problems with these data derive from the heterogeneity of the 
treated patients with respect to disease course and stage, from the fact that most 
studies have been open, uncontrolled trials, and from differences in the transplant 
regimens that have been used. Nevertheless, the most important aspects, i.e. patient 
eligibility, transplant regimen, and also the mechanistic understanding have 
advanced substantially, and a consensus has been reached between European- and 
North American investigators that aHSCT is best applied in patients of 45 years or 
younger, within the first five years after diagnosis, with aggressive RRMS, and using 
the BEAM-ATG regimen. Below, we will provide more detail regarding the most 
important aspects of patient selection and transplant regimen.  
 
 Figure 1 
Proposed therapy algorithm in Multiple Sclerosis (adapted [8]) 
 
  
Patient eligibility criteria – who is a candidate? 
 From the above reasons treatment responses to aHSCT have been less clear 
in SPMS patients, and the fraction of patients, who show sustained improvement for 
more than 1 EDSS point is much larger in RRMS patients [8]. There is currently no 
doubt that aHSCT is most effective in highly active RRMS patients. Identification of 
MS patients, who are best suited for aHSCT, is one of the most important aspects for 
successful treatment. Patients should still be in the early stages of the disease, i.e. 
ideally within 5 years after diagnosis, and have a high risk for rapid disease 
progression, i.e. have aggressive MS [9]. Reliable prognostic predictors for an 
aggressive course are, however, still lacking, and so far the best approach is to 
combine clinical relapse activity, MRI activity and failure to respond to first-line- 
and/or second line treatment. In a recent manuscript that summarized the consensus 
among specialists, who pursue aHSCT, highly active RRMS has been defined as 
follows:  
 at least 1 severe clinical relapse (ΔEDSS ≥ 1 with Functional Severity Score 
(FSS) ≥2 in motor, cerebellar or brain stem function in the year prior to 
evaluation, 
disease progression (highly active RRMS)
consider aHSCT (patient < 45 years, 2.5 ≤ EDSS ≥ 5.5)
disease progression
escalation therapy (Natalizumab, Fingolimod, others)
MS diagnosis
start DMD (GA, IFN-β, others)
≤ 5 years from
Initiation of DMD
2.5 ≤ EDSS ≥ 5.5
 ≥1 gadolinium-positive (Gd+) lesion of diameter ≥3 mm or accumulation of 
≥0.3 T2 lesions/ month in two consecutive MRI 6-12 months apart. 
Furthermore patients qualify for aHSCT after failure of conventional best treatment, 
which is currently natalizumab. Whether aHSCT can already be considered after 
failure of first line therapy and prior to further escalation steps is still under discussion 
[9], but unlikely to be accepted by a broader number of MS neurologists before formal 
proof of the superiority of aHSCT over most active conventional therapies has been 
provided. 
 Patients considered for aHSCT should be younger than 45 years. This is 
based on increasing transplant-related mortality in patients aged over 40 years [3], 
which may be related to immunosenescence and/or less efficient immune 
reconstitution in MS patients above this age [3]. Furthermore, patients over 40 years 
are at increased risk to shift quicker to the secondary progressive phase of the 
disease [10], during which the benefit of aHSCT is clearly reduced. The path of 
treatment escalation and eligibility criteria are briefly summarized in Fig. 1. 
 
Stem cell mobilization and conditioning regimen  
 The main assumption of how aHSCT acts is that an aberrant immune system 
that underlies the autoimmune disease is eliminated by chemotherapeutic drugs and 
subsequently a new and again tolerant immune system is installed by infusing the 
patient with his/her own hematopoietic stem cells that have been collected prior to 
conditioning. Along this rationale one important question is how intense and complete 
the conditioning regimen has to be, i.e. if most of hematopoietic stem cells need to be 
eliminated (myeloablative) or if it is sufficient to deplete lymphocytes 
(lymphoablative). The former absolutely requires stem cell rescue and carries 
substantially higher risk. Several transplant regimens including more intense ones 
with whole body irradiation, with different chemotherapeutic agents, changes in graft 
mobilization and/or manipulation, or also less intensive lymphoablative regimens 
have been explored during the last 20 years (for review, see reference [4]). Careful 
assessment and continuous discussion among aHSCT specialists have led to 
consensus that the best experience currently exists for the BEAM-ATG regimen, 
which has been used most frequently in Europe in the last 15 years. Peripheral Blood 
Haematopoietic Stem Cells (PBSC) are collected by leukapheresis after mobilization 
by cyclophosphamide (2-4 g/m2 total dose over 1-2 days) and subsequent treatment 
with granulocyte colony-stimulating factor (G-CSF, 5-12 µg/kg/day) [4, 11]. Stem cell 
mobilization is also possible with G-CSF alone, but may lead to MS relapses [12]. 
Including cyclosphosphamide not only increases the efficacy of mobilization, but 
probably also reduces the number of autoreactive T cells and inflammatory activity 
prior to harvesting stem cells. HSCs are then collected and cryopreserved until 
transplantation. Experience has shown that a number of 3x106 CD34+ cells /kg is 
safe for the patient [4]. The intermediate-intensity conditioning regimen BEAM 
consists of 300mg/m2 carmustine, at day -6, 200mg/m2 etoposide and 200mg/m2 
cytarabine at days -5 to day -2 and 140mg/m2 melphalan at day -1. This regimen has 
shown a good safety/efficacy profile in lymphoproliferative diseases and in MS was 
associated to peri-transplant in vivo i.v. anti-thymocyte globulin (ATG, 5-7.5mg/kg in 
2-3 days) (see Fig. 2) [3]. Some studies tested a lymphoablative low-intensity 
regimen (cyclophosphamide and ATG/alemtuzumab), which shows reduced toxicity, 
but is less effective in stopping relapse- or in general inflammatory CNS activity (MRI) 
[13]. To reduce autoreactive lymphocytes from the graft different methods have been 
used, including ex-vivo positive selection of CD34+ cells prior to cryopreservation. In 
MS, an evidence of a clinical benefit of graft manipulation is lacking and mobilization 
with cyclophosphamide plus ATG administration as in-vivo T-cell depletion is now the 
preferred standard [9]. Besides BEAM-ATG, for which the experience is currently 
most extensive, a regimen with busulphan/cyclophosphamide/ATG  combined with 
positive selection of CD34+ cells of the graft emerges as another highly effective 
aHSCT protocol with a good safety profile after the shift to low-dose, iv busulphan 
[14]. 
 
 
 Figure 2 
Protocol for BEAM/ATG regimen in aHSCT. Stem cell mobilization with cyclophosphamide (Cy) and 
G-CSF. Conditioning regimen with carmustine, etoposide, cytarabine and melphalan, followed by 
autologous stem cell infusion. In vivo T cell depletion is performed by anti-thymocyte globulin (ATG). 
 
 
Adverse events and risks of aHSCT 
 The transplant-related mortality (TRM) is the major risk for the patients 
undergoing aHSCT in AD. During the first years (1995-2000) TRM was around 7.4% 
but decreased from 2001–2007 to 1.3% [4] as experience of the centres has been 
increasing, patient selection improved and toxicity of the protocols decreased. Higher 
toxicity was observed with regimens including oral busulphan or whole body 
irradiation [3]. Conversely low-intensity treatments posed less toxicity, but were also 
less effective for preventing relapses of MS [15]. Pro and contra of myeloablative 
versus non-myeloablative regimens are still controversially discussed [9, 16]. 
 Early side effects are mostly caused by immunosuppression and include 
neutropenic fever, sepsis, CMV reactivation, urinary tract infection, gastroenteritis, 
pneumonia and generalized HSV infection as expected for aHSCT in other diseases 
[3]. Other adverse events were allergy to ATG, engraftment syndrome, veno-
occlusive disease, thrombotic thrombocytopenic purpura and mucositis, especially in 
the late phase [3]. Typical long-term risks are development of a secondary 
autoimmune disease (about 12% of patients underwent aHSCT for autoimmune 
disease develop a secondary autoimmune disease after a median of 22 months [17]). 
Only one case with a secondary malignancy out of 345 MS patients registered in the 
EBMT database from 1997-2007 was described [18]. 
d -60 til
d -30
d -7 d -6, d -4
d -3, d -2
d 0
Cy 2-4g/m2 
total, 1-2 days
followed by
G-CSF 5-12 
µg/kg/ day
until 2-3x106
CD34+ cells/kg 
harvested
300mg/m2
carmustine
200mg/m2
etoposide
and 
200mg/m2
cytarabine
d -1
140mg/m2
melphalan
d +1
d +2
ATG
5-7.5mg/kg
HSC
infusion
stem cell
mobilization
conditioning regimen HSC infusion T cell
depletion
time
 Immune reconstitution and mechanisms of aHSCT 
 The mechanisms of action of aHSCT are still only partially understood. The 
clinical experience of long lasting and complete cessation of disease activity with 
improvement of clinical disability in many patients after aHSCT during the early 
stages of RRMS suggest that the above premise, i.e. elimination of an aberrant 
immune system and de novo development of a tolerant/normal immune system, is 
met and that aHSCT comes close to even curing the disease [4, 18, 19]. Data from 
Muraro et al., who demonstrated in a prospective study of 7 patients receiving an 
intense conditioning regimen (total body irradiation and cyclophosphamide), support 
this notion and showed that the newly emerging T cell repertoire comes from recent 
thymic emigrants and is not only broader, but also indicated complete renewal [20]. 
Numbers of B cells, NKTs and CD3+ T cells were normal with inverted CD4/CD8 
ratio within the first 3 month after aHSCT, whereupon the extra-thymic pathway 
seems to be predominant in the first year after aHSCT [20-23]. At this stage 
lymphopenia causes homeostatic proliferation, whereas myelin-reactive T cells 
undergo activation-induced cell death [24, 25]. While replenishment of CD4+ T cells 
lags behind other immune cells during the first year, their renewal picks up during the 
second year and overall T cell diversity increases [26, 27]. Further, similar numbers 
of myelin basic protein-reactive T cells were observed after autologous HSCT when 
compared to before the procedure, but after 12 months these MBP-reactive T cells 
showed a more heterogeneous epitope recognition pattern than at baseline [28]). 
Studies in experimental autoimmune encephalomyelitis (EAE), the main animal 
model of MS, demonstrated an increased frequency of regulatory T cells, a shift in T 
cell myelin epitope recognition and a reduction of anti-myelin antibodies after 
syngeneic bone marrow transplantation [29]. While the above data on T cell 
repertoire renewal and elimination of autoreactive T cell clones are relatively 
complete, there is overall less data on how completely the B cell repertoire and 
antibody profiles are exchanged following aHSCT. Since oligoclonal immunoglobulin 
G bands (OCB) in the cerebrospinal fluid are a diagnostic hallmark of MS and may 
indicate a certain degree of compartmentalization of the autoimmune process in the 
CNS, it would be important to examine if they disappear as well as comprehensive 
profiling of the B cell/antibody repertoires before and after aHSCT. Preliminary data 
indicate that OCB may disappear after aHSCT and remain in some patients, but 
these studies are not conclusive in the moment. When considering the homing of 
long-lived plasma cells to the bone marrow and the relative resistance of these cells 
to chemotherapy, it is possible that even intense regimen may not completely 
eliminate them, and that it will then depend on the question if continued or new 
disease activity requires T cells or can independently be driven by pathogenic B-
/plasma cells alone. That antibody-producing cells survive the conditioning regimen is 
indicated by the at least partially maintained vaccination status to some antigens after 
aHSCT (for recommendations regarding vaccination after HSCT see Ljungman et al. 
[30]). Mechanistic reasons for the poor/incomplete response to aHSCT in patients, 
who have secondary- or primary progressive disease [3], may relate to the extent of 
prior damage of CNS tissue, which is then predestined to slowly progressive 
neuronal loss and/or to chronic activation of microglial cells and maturation of 
reactive astrocytes from glial progenitors in response to the inflammatory injury in the 
CNS as shown by Cassiani-Ingoni et al. in the EAE model [31]. According to their 
data microglia is not or only incompletely affected by aHSCT. 
 An important question that relates to the assumption of immune reconstitution 
as basis for the efficacy of aHSCT is if it is likely that patients may re-develop MS 
despite successful immune repertoire exchange since they receive their own stem 
cells, which carry in principle the genetic risk factors that predispose to MS. Clinical 
experience shows that a small subgroup of patients indeed re-develop MS even after 
receiving the currently best aHSCT regimen [4], however, it is currently not clear if 
these patients a) carry a higher number of MS risk loci than those, who remain free of 
new activity, or b) if they encountered environmental triggering factors, or c) if the 
prior damage of CNS tissue and subsequent death of cells releases autoantigens 
and this is involved in new disease activity. These questions should be addressed in 
detail in the future. As a first step towards examining these issues Lutterotti et al. 
studied the genome-wide gene expression and microRNA profile of CD34+ 
hematopoietic precursor cells of MS patients and healthy donors to address if 
alterations are already found in these precursor cells. Their results indicate that there 
are no significant differences between CD34+ hematopoietic progenitor cells of MS 
patients and healthy donors [32].  
 
  
Summary and future directions 
 During the last two decades aHSCT and its various aspects have been 
explored in detail, and the experience can be summarized as follows. Based on 
casuistic evidence, data from open and uncontrolled studies and the yet unpublished 
controlled comparison of BEAM-ATG versus mitoxantrone aHSCT (ASTIMS) leads to 
complete cessation of disease activity in the vast majority of RRMS patients with 
aggressive MS fulfilling the above criteria. Furthermore, the ASTIMS data shows 
even in a small phase IIb study that aHSCT is significantly more effective than one of 
the most effective, currently available drugs, mitoxantrone (Mancardi, G., Saccardi, 
R., personal communication). Furthermore, the risk of transplant-related mortality has 
dropped to acceptable levels in this population of patients. Mechanistic studies 
support the rationale of aHSCT to abrogate an autoreactive immune repertoire and 
re-install a healthy immune system. Despite these clear advances, acceptance of 
aHSCT in the neurological community remains low probably due to the continuing 
false perception of unacceptable risk, the complexity of the treatment, which requires 
close interaction between MS neurologists and hematologist/transplant specialist, 
and the increasing number of treatments that offer a good compromise of acceptable 
benefit/risk ratio and easier administration. Despite the latter, existing data indicate 
that even the most effective available drugs need to be given continuously, that 
particularly the most effective therapies carry substantial risk, and that they are 
expected to be inferior to aHSCT regarding their efficacy. Further, aHSCT is a one 
time treatment with no need for continuing immunomodulation, and, when 
considering the cost of currently available treatments of up to 45.000 USD/year, will 
lead to substantial socioeconomic benefit in patients with aggressive MS. What is 
needed most, however, is definitive evidence for superiority of aHSCT over best 
available therapy of MS by a controlled, multi-center trial. Following several years of 
intense discussions among European and North-American investigators the main 
aspects of such a trial have now been outlined and recently published [9]. Since a 
phase III trial of aHSCT versus conventional treatment will not be sponsored by 
industry, the main challenge ahead is to raise interest and funds from public 
organizations such as e.g. the European Community in order to provide the missing 
evidence. 
 
 
 
Literature 
 
1. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7(3):268-77.  
2. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, 
 and genetics. Curr Opin Neurol. 2012;25(3):246-51.  
3. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autologous stem cell 
 transplantation for progressive multiple sclerosis: update of the European Group for Blood and 
 Marrow Transplantation autoimmune diseases working party database. Mult Scler. 
 2006;12(6):814-23.  
4. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. 
 Lancet Neurol. 2008;7(7):626-36.  
5. Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V et al. Efficacy of disease-
 modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur 
 Neurol. 2008;60(1):1-11.  
6. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Long-term effect of 
 early treatment with interferon beta-1b after a first clinical event suggestive of multiple 
 sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 
 2009;8(11):987-97.  
7. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A et al. Effect of glatiramer acetate 
 on conversion to clinically definite multiple sclerosis in patients with clinically isolated 
 syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 
 2009;374(9700):1503-11.  
8. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP et al. Autologous 
 haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in 
 multiple sclerosis: the Italian multi-centre experience. Mult Scler. 2012;18(6):835-42.  
9. Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM et al. A prospective, 
 randomized, controlled trial of autologous haematopoietic stem cell transplantation for 
 aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825-34.  
10. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in 
 multiple sclerosis. Neurology. 2011;77(13):1246-52.  
11. Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT et al. Hematopoietic stem cell 
 transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate 
 international clinical studies. Biol Blood Marrow Transplant. 2010;16(8):1076-83.  
12. Openshaw H, Atkins HL, Chen JT, de Bittencourt PR, Griffith LM, Kerr DA et al. Multiple sclerosis 
 conference synopsis and discussion: cellular therapy for treatment of autoimmune diseases 
 (October 2005). Mult Scler. 2006;12(6):824-5.  
13. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G et al. Autologous non-
 myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: 
 a phase I/II study. Lancet Neurol. 2009;8(3):244-53.  
14. Atkins H, Freedman M. Immune ablation followed by autologous hematopoietic stem cell 
 transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol. 
 2009;549:231-46.  
15. Atkins HL, Muraro PA, van Laar JM, Pavletic SZ. Autologous hematopoietic stem cell 
 transplantation for autoimmune disease--is it now ready for prime time? Biol Blood Marrow 
 Transplant. 2012;18(1 Suppl):S177-83.  
16. Burt RK, Balabanov R, Voltarelli J, Barreira A, Burman J. Autologous hematopoietic stem cell 
 transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard 
 immune suppressive drugs and if no inflammation, no response'. Mult Scler. 2012;18(6):772-5.  
17. Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I et al. Secondary autoimmune 
 diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT 
 Autoimmune Disease Working Party. Blood. 2011;118(6):1693-8.  
18. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous 
 hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 
 12 years' experience from the European Group for Blood and Marrow Transplantation Working 
 Party on Autoimmune Diseases. Haematologica. 2010;95(2):284-92.  
19. Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F et al. Brazilian 
 experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse 
 ATG and CY/rabbit ATG. Bone Marrow Transplant. 2010;45(2):239-48.  
20. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R et al. Thymic output 
 generates a new and diverse TCR repertoire after autologous stem cell transplantation in 
 multiple sclerosis patients. J Exp Med. 2005;201(5):805-16.  
21. Carreras E, Saiz A, Marin P, Martinez C, Rovira M, Villamor N et al. CD34+ selected autologous 
 peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment 
 results at one year of follow-up in 15 patients. Haematologica. 2003;88(3):306-14.  
22. Saiz A, Blanco Y, Carreras E, Berenguer J, Rovira M, Pujol T et al. Clinical and MRI outcome after 
 autologous hematopoietic stem cell transplantation in MS. Neurology. 2004;62(2):282-4.  
23. Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH et al. Treatment of autoimmune 
 disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell 
 transplantation. Blood. 1998;92(10):3505-14.  
24. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest autoimmune aggression. Trends 
 Immunol. 2006;27(2):61-7.  
25. Kieper WC, Troy A, Burghardt JT, Ramsey C, Lee JY, Jiang HQ et al. Recent immune status 
 determines the source of antigens that drive homeostatic T cell expansion. J Immunol. 
 2005;174(6):3158-63.  
26. Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L et al. Assessment of thymic 
 output in adults after haematopoietic stem-cell transplantation and prediction of T-cell 
 reconstitution. Lancet. 2000;355(9218):1875-81.  
27. Hug A, Korporal M, Schroder I, Haas J, Glatz K, Storch-Hagenlocher B et al. Thymic export 
 function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J 
 Immunol. 2003;171(1):432-7.  
28. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G et al. Characteristics of T-cell receptor 
 repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell 
 grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008.  
29. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Boscke R, Budach W et al. 
 Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood. 
 2005;106(5):1875-83.  
30. Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R et al. Vaccination 
 of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party 
 of the EBMT. Bone Marrow Transplant. 2005;35(8):737-46.  
31. Cassiani-Ingoni R, Muraro PA, Magnus T, Reichert-Scrivner S, Schmidt J, Huh J et al. Disease 
 progression after bone marrow transplantation in a model of multiple sclerosis is associated 
 with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol. 
 2007;66(7):637-49.  
32. Lutterotti A, Jelcic I, Schulze C, Schippling S, Breiden P, Mazzanti B et al. No proinflammatory 
 signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Mult Scler. 
 2012;18(8):1188-92.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
aHSCT autologous hematopoietic stem cell transplantation 
CIS  clinically isolated syndrome 
CNS  central nervous system 
Cy  cyclophosphamide 
EAE  experimental autoimmune encephalomyelitis 
EBMT  european group for blood and marrow transplantation 
EBV  Epstein-Barr virus 
GA  glatiramer acetate  
INF-β  interferon- β 
MS  multiple sclerosis  
OCB  oligoclonal bands 
SPMS  secondary progressive multiple sclerosis 
PML  progressive multifocal leukencephalopathy 
PPMS  primary progressive multiple sclerosis 
RRMS relapsing remitting multiple sclerosis 
TRM  transplant-related mortality 
 
 
